drugset / Trial / NCT07639099

Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression

NCT07639099

Phase 4 Not yet recruiting 164 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Esketamine has rapid-onset antidepressant effects and may reduce postpartum depression in parturients with prenatal depressive symptoms. However, its adverse neuropsychiatric symptoms limits clinical application. Dexmedetomidine can alleviate these adverse symptoms and has independent antidepressant effect. This randomized, double-blind, placebo-controlled trial is designed to evaluate whether intranasal esketamine combined with dexmedetomidine can reduce the prevalence of postpartum depression in women with prenatal depressive symptoms.

Timeline

Start
2026-06
Primary completion
2029-10
Completion
2029-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.4 ug/kg Intranasal
Subject Esketamine Other / unclassified 0.2 mg/kg Intranasal

Indications